Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II gemcitabine + docetaxel as first-line therapy in metastatic breast cancer
2005-006168-71Phase 2Active
- Sponsor
- ASL 2 Savonese
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in breast cancer, sponsored by ASL 2 Savonese. Primary endpoint: Objective response rate. Started Jun 2006; status: active.
02
Drugs
docetaxelgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-006168-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006168-71.